Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 436

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 436
---
| Options cancelled (Successor)               |     |             | (1,662 | ) |     | $         | 2,922.40 |     |             |    - |
| Balance, December 31, 2024 (Successor)      |     |             |  3,247 |   |     | $         |   200.00 |     |             | 9.64 |
| Options exercisable as of December 31, 2024 |     |             |  2,474 |   |     | $         |   200.00 |     |             | 9.68 |

The intrinsic value of Predecessor
options exercised during the year ended December 31, 2023 was $. No options were exercised in the Successor period from February
14, 2024 to December 31, 2024.

On March 25, 2024, the stockholders
approved the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and 2024 Employee Stock Purchase
Plan (“2024 ESPP”), with an initial reserve of and shares of common stock, respectively. The 2024 Plan and 2024
ESPP became effective on February 14, 2024 in connection with the closing of the Business Combination. At a special meeting of stockholders
on April 30, 2024, the stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the number
of shares that may be issued pursuant to incentive stock options, by an additional shares each. At a special meeting of stockholders
on November 11, 2024, the stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the
number of shares that may be issued pursuant to incentive stock options, by an additional shares each. As of December 31, 2024,
no awards have been granted under the 2024 ESPP. The 2024 Plan has an evergreen provision that allows for an annual increase in the number
of shares available for issuance under the 2024 Plan to be added on the first day of January, starting with January 1, 2025, in an amount
equal to the lesser of (i) % of the fully diluted shares of our Common Stock on the immediately preceding December 31 or (ii) such number
of shares as